New mitomycin formulation for low-grade upper tract urothelial cancer

Abstract

Although patients with high-grade upper tract urothelial cancer are routinely managed with radical nephroureterectomy, some subsets of patients with low-grade disease might initially be offered renal-sparing approaches such as endoscopic ablation, even though many of these patients will ultimately require radical nephroureterectomy. Because this disease is most common in patients aged 60 years and older, better therapeutic options than this high-risk surgery need to be introduced to bring nephron-sparing approaches into clinical practice.